DECHENG CAPITAL LLC
Q4 2023 Form 13-F

MENLO PARK, CAYMAN ISLANDS
CIK 0002010850 · CRD 293073 · SEC-registered investment adviser
$357.9M Reported Value Total

DC GLOBAL VENTURES reports 5 total accounts under management (AUM). There are 5 discretionary accounts valued at $1,802,579,659, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
8 funds · $2.7B gross asset value
Venture Capital Fund: $2.5B · Hedge Fund: $228.2M
Source: Form ADV filed 2026-03-31
Reported value
$357.9M
Quarter over quarter
0.0%
Holdings
24
Top-10 concentration
84.6%

Key People

Form ADV owners & control persons
Xiangmin Nmn Cui
MANAGING DIRECTOR
Hongbo Nmn Bao
CHIEF COMPLIANCE OFFICER
Yuheng Nmn Qiu
CHIEF FINANCIAL OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q4 2023 13F record

Q4 2023 13F filing summary

Q4 2023 Form 13F portfolio summary
Period of report December 31, 2023
Filed February 12, 2024
Form 13F-HR
Reported value $357.9M
Positions 24
Change in reported value First reported quarter
Top-10 concentration 84.6%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 13, 2026
11 $685.1M
Q2 2026 13F
Filed Aug 14, 2026
14 $731.7M
Q1 2026 13F
Filed May 13, 2026
14 $661.3M
Q4 2025 13F
Filed Feb 12, 2026
19 $743.4M
Q3 2025 13F
Filed Nov 14, 2025
23 $573.2M
Q2 2025 13F
Filed Aug 13, 2025
25 $396.0M
Q1 2025 13F
Filed May 8, 2025
27 $356.5M
Q4 2024 13F
Filed Feb 14, 2025
28 $466.2M
Q3 2024 13F
Filed Nov 15, 2024
26 $422.2M
Q2 2024 13F
Filed Aug 14, 2024
24 $326.3M
Q1 2024 13F
Filed May 14, 2024
22 $745.6M
Q4 2023 13F
Filed Feb 12, 2024
24 $357.9M

Top 20 holdings · Q4 2023

Largest Q4 2023 13F positions by reported value
# Holding Reported value % of portfolio
1 ALPN Alpine Immune Sciences, Inc. $135.0M 37.72%
2 ZNTL Zentalis Pharmaceuticals Inc. $31.8M 8.89%
3 PACB Pacific Biosciences of California, Inc. $28.8M 8.06%
4 TXG 10x Genomics, Inc. $20.1M 5.62%
5 IMGN IMMUNOGEN INC $19.6M 5.47%
6 RCUS Arcus Biosciences, Inc $16.6M 4.64%
7 KRTX KARUNA THERAPEUTICS INC $14.9M 4.16%
8 ROIV ROIVANT SCIENCES LTD $14.4M 4.02%
9 ILMN Illumnia, Inc. $11.3M 3.15%
10 ARGX Argenx SE $10.4M 2.92%
11 SLRN ACELYRIN INC(NSM) $10.2M 2.86%
12 KRYS KRYSTAL BIOTECH INC $8.2M 2.28%
13 PHAT PHATHOM PHARMACEUTICALS INC $7.8M 2.17%
14 LNTH LANTHEUS HOLDINGS INC(NMS) $5.7M 1.6%
15 TERN Terns Pharmaceuticals, Inc. $4.6M 1.3%
16 AURA Aura Biosciences, Inc. $4.6M 1.28%
17 BYSI BeyondSpring Inc. $4.5M 1.24%
18 EQ Equillium Inc. $3.2M 0.9%
19 ATRC AtriCure Inc. $1.7M 0.46%
20 HLTH Cue Health Inc. $1.5M 0.41%

Values as reported on the Q4 2023 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings